News ReleaseView printer-friendly version
Quidel Corporation Appoints S. Wayne Kay President, COO
SAN DIEGO, Dec. 13 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL) announced today the appointment of S. Wayne Kay as President and Chief Operating Officer of Quidel, effective January 1, 2001. Mr. Kay will report to Andre de Bruin, current President and Chief Executive Officer, who will continue in his role as CEO.
"We are extremely pleased to welcome someone with Wayne's unparalleled business expertise," said Mr. de Bruin. "Wayne brings with him knowledge of every aspect of the medical device and supplies industry, built up over 25 years of experience. He has run a multinational healthcare corporation and headed a diagnostic device start up focused on point-of-care quantitative measurement devices."
Mr. Kay comes to Quidel from Neoforma.com, where he has served as Senior Vice President since 1999. From 1994 to 1999, Mr. Kay served as President and CEO of the Health Industry Distributors Association. Mr. Kay also served as President and CEO of Enzymatics, Inc. from 1989 to 1994. Additionally, Mr. Kay worked at SmithKline Beecham from 1973 through 1989, where he became President of SmithKline Diagnostics.
"I'm excited about this opportunity," said Mr. Kay. "Quidel has significant growth potential and is well-positioned to provide leadership in the rapid point-of-care healthcare diagnostics market, particularly with its recent business acquisitions. I am looking forward to working with Andre and the management team to help achieve successful results with these initiatives."
Mr. Kay has an MBA in Management from Pepperdine University and has received a BS in Business Administration from the University of San Francisco as well as a BS in Microbiology from the Virginia Polytechnic Institute. Mr. Kay also serves on several boards, including Health Industry Business Communications Council and the Boys and Girls Clubs of America.
Quidel Corporation discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid cost-effective diagnostic information for acute and chronic conditions that affect women's health throughout the phases of their lives, including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, Chlamydia and infectious mononucleosis. Quidel's products are sold to healthcare professionals for use in physicians' offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information to enable rapid treatment and improve health outcomes, lower costs, and increase patient satisfaction.
This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results and performance of Quidel's products, such that actual results and performance may differ materially. If Quidel's products fail to perform as expected, or if there is lower consumer demand for these products than expected, Quidel's financial condition and operating results may be materially and adversely affected. Quidel's financial condition and operating results may also be materially and adversely affected by a number of other factors, including, without limitation, seasonality, adverse changes in competitive and economic conditions, actions by the Company's distributors, manufacturing and production delays or difficulties and adverse actions or delays in product reviews by the FDA. Please see the discussion of these and other factors in Quidel's annual reports on Form 10-K and subsequent quarterly reports on Form 10-Q. For more information, please visit Quidel's web site at http://www.quidel.com.
Investor Relations Associate
212-696-4455 ext. 242